| Literature DB >> 25422367 |
Patricia M Gaffney1, Bradd Barr1, Joan D Rowe1, Cyrus Bett1, Ioannis Drygiannakis1, Federico Giannitti1, Margarita Trejo1, Majid Ghassemian1, Patrice Martin1, Eliezer Masliah1, Christina J Sigurdson2.
Abstract
Pathologic amyloid accumulates in the CNS or in peripheral organs, yet the mechanism underlying the targeting of systemic amyloid deposits is unclear. Serum amyloid A (SAA) 1 and 2 are produced predominantly by the liver and form amyloid most commonly in the spleen, liver, and kidney. In contrast, SAA3 is produced primarily extrahepatically and has no causal link to amyloid formation. Here, we identified 8 amyloidosis cases with amyloid composed of SAA3 expanding the uterine wall of goats with near-term fetuses. Uterine amyloid accumulated in the endometrium, only at the site of placental attachment, compromising maternal-fetal gas and nutrient exchange and leading to fetal ischemia and death. No other organ contained amyloid. SAA3 mRNA levels in the uterine endometrium were as high as SAA2 in the liver, yet mass spectrometry of the insoluble uterine peptides identified SAA3 as the predominant protein, and not SAA1 or SAA2. These findings suggest that high local SAA3 production led to deposition at this unusual site. Although amyloid A (AA) amyloid deposits typically consist of an N-terminal fragment of SAA1 or SAA2, here, abundant C-terminal peptides indicated that the uterine amyloid was largely composed of full-length SAA3. The exclusive deposition of SAA3 amyloid in the uterus, together with elevated uterine SAA3 transcripts, suggests that the uterine amyloid deposits were due to locally produced SAA3. This is the first report of SAA3 as a cause of amyloidosis and of AA amyloid deposited exclusively in the uterus. © FASEB.Entities:
Keywords: amyloid; mass spectrometry; protein misfolding
Mesh:
Substances:
Year: 2014 PMID: 25422367 PMCID: PMC6137862 DOI: 10.1096/fj.14-256081
Source DB: PubMed Journal: FASEB J ISSN: 0892-6638 Impact factor: 5.191